May 7, 2024Open Access

Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

To compare the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and camrelizumab or with sorafenib alone in patients with intermediate or advanced hepatocellular carcinoma (HCC).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Sun et al. (Tue,) studied this question.

synapsesocial.com/papers/68e6b2a9b6db643587634567 https://doi.org/https://doi.org/10.1093/bjr/tqae087

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The clinical efficiency of TACE combined with simultaneous computed tomography‐guided radiofrequency ablation for advanced hepatocellular carcinoma2021 · 26 citations
2Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma2019 · 293 citations
3Hepatocellular carcinoma2021 · 245 citations
4Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification1999 · 3,802 citations
5Hepatocellular Carcinoma.1977 · 2,096 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo